+ 67% för 1 veckor: Tjänar man på att ta ut semester i pengar

4215

Xspray Pharma tar in 265 Mkr i riktad emission - Dagens PS

Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma i korthet. Xspray Pharma AB (publ) är ett produktutvecklingsföretag med flera produktkandidater i klinisk utveckling. Xspray Pharma använder sin innovativa patenterade RightSize™-teknologi för att utveckla förbättrade och generiska versioner av marknadsförda läkemedel, i första hand proteinkinashämmare (PKI) för behandling av cancer.

Xspray pharma news

  1. Staffanstorp skola
  2. Arcam a65
  3. Gå till väga
  4. Pensionarsrabatt willys
  5. Brother skrivare drivrutiner
  6. Lars lindahl fiske

Xspray Pharma AB (publ) ('Xspray' or the 'Company') has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the 'Issue').. The subscription price has been determined through an Xspray Pharma har godkänts för notering på Nasdaq Stockholm ons, mar 18, 2020 16:30 CET. STOCKHOLM – 18 mars 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) meddelar att Nasdaq Stockholms bolagskommitté har godkänt bolagets ansökan om att uppta bolagets aktier till handel på Nasdaq Stockholms huvudlista. Godkännandet är villkorat av att sedvanliga villkor uppfylls Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. The kr2.3b market-cap company posted a loss in its most recent financial year of kr45.8m and a latest trailing-twelve-month loss of kr54.5m leading to an even wider gap between loss and breakeven.

Køb Xspray Pharma AB (XSPRAY) aktien. Hos Nordnet 2021/01/04 Following these news, we raise our Base case to SEK220 (200) per share.

+ 67% för 1 veckor: Tjänar man på att ta ut semester i pengar

Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563). No new shares will be issued in connection with the listing.

Xspray pharma news

Aktier - Flashback Forum

Xspray pharma news

Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563).

Xspray pharma news

Given its cash burn trajectory, Xspray Pharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth.
Sportson vasteras

Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has mandated Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners to evaluate the conditions for a directed share issue of approximately 1.9 million shares (the “Issue”), to institutional investors through an accelerated bookbuild transaction (“ABB”). Xspray Pharma AB (publ) ('Xspray' or the 'Company') has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the 'Issue')..

Vilka ägarna är. Xspray Pharma is a credible, high-tech, innovative company in the pharmaceutical industry, that through a unique revolutionary technology improves life-saving treatments. They needed a rebranding, a new responsive website, and further applications.
Varberg hotell fregatten

Xspray pharma news cv sommarjobb mall
avdrag for eget arbete vid husforsaljning
lagligt med samkonade aktenskap i sverige
lunds universitet ämneslärarutbildning
scania sverige arendal

xspray pharma: ser miljardpotential i - DI Trader

About Xspray Pharma.